CURRICULUM VITAE

Lydia Aoun-Barakat, MD

Version Date: 2/10/2024

Contact Information:

Address	135 College Street Ste Suite 323 New Haven, CT 06510
Phone:	1 (203) 688-2685
Email:	lydia.barakat@yale.edu

School: Yale School of Medicine

Education:

01/1986 - 01/1994	MD, Lebanese University, Beirut, Beirut Governorate, Lebanon

Career/Academic Appointments:

07/1995 - 06/1998	Resident, Internal Medicine, Griffin Hospital, Derby, CT
01/1998 - 01/2000	Fellow, Infectious Diseases , Yale New Haven Hospital, New Haven, CT
07/1998 - 06/2000	Postdoctoral Fellow, Infectious Diseases, Yale School of Medicine, New Haven, CT
07/2001 - 06/2003	Clinical Instructor, Internal Medicine, Yale School of Medicine, New Haven, CT
01/2005 - 07/2008	Assistant Clinical Professor, Internal Medicine, Yale School of Medicine, New Haven, CT
07/2008 - 06/2010	Associate Clinical Professor, Internal Medicine, Yale School of Medicine, New Haven, CT
07/2010 - 06/2016	Assistant Professor, AIDS, Yale School of Medicine, New Haven, CT
07/2016 - 06/2026	Associate Professor on Term, AIDS, Yale School of Medicine, New Haven, CT

Administrative Positions:

2010 - 2023	Medical Director Nathan Smith Clinic, Infectious Diseases, Yale School of Medicine, New Haven, CT
2011 - Present	Program Director, HIV Primary Care Training Track, Internal Medicine, Yale School of Medicine, New Haven, CT
2020 - Present	Project Director, Connecticut New England AIDS Education Training Center, HRSA, New Haven, CT
2021 - Present	Director, Yale Infectious Diseases Ambulatory Services, Infectious Diseases, Yale School of Medicine, New Haven, CT

2023 - Present	Director, Yale Center for Infectious Diseases, Infectious Diseases, Yale School of Medicine, New Haven, CT

Board Certification:

2001 - 2011	AB of Internal Medicine, Infectious Disease
2011 - 2021	AB of Internal Medicine, Infectious Disease, recertification
1998 - 2020	AB of Internal Medicine, Internal Medicine
2020 - 2022	AB of Internal Medicine, Internal Medicine, recertification

Professional Honors & Recognition:

International/National/Regional

2008	Senior Leadership in Quality HIV care Award, National Quality Center- HRSA
2019	Leadership Award, Connecticut Infectious Disease Society

Yale University/Yale School of Medicine/Hospital System

2008	Teacher of the Year Award, Yale Primary Care Program
2012	Teacher of the Year Award, Yale Primary Care Program
2017	Teacher of the Year Award, Yale Internal Medicine Residency Program
2018	100 Women in Medicine
2021	Teacher of the Year Award, Yale Internal Medicine Residency Program
2022	The Stephen Huot Award for Dedication and Excellence, Yale Primary Care Program

Other

2022	Elsie Cofield Award, New Haven Mayor Task Force on AIDS

Grants/Clinical Trials History:

Current Grants

Agency:	HRSA
I.D.#:	5U10-HA29294-0600
Title:	New England AIDS Education and Training Center
P.I.:	Lydia Aoun Barakat
Role:	Local PI
Percent effort:	15%
Total costs:	$400,000.00
Project period:	07/01/2020

Agency:	HRSA
I.D.#:	6 H97HA46082-01-01
Title:	HIV and Aging SPNS

P.I.: Lydia Aoun Barakat
Role: P.I.
Percent effort: 10%
Total costs: $300,000.00
Project period: 08/01/2022

Current Clinical Trials

Agency: National Institute on Aging (NIA)
I.D.#: 0409027018
Title: Toll-like Receptors in Older Adults and Response to Vaccination
P.I.: Albert C Shaw
Role: Sub-Investigator
Percent effort: N/A
Total costs: 0.0000
Project period: 09/24/2004 - ongoing

Agency: National Cancer Institute (NCI)
I.D.#: 1406014146
Title: Pathogenesis and treatment of HIV-associated disease
P.I.: Brinda Emu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/11/2014 - ongoing

Agency: National Cancer Institute (NCI)
I.D.#: 1407014364MRR
Title: Cancers in Individuals with HIV Infection
P.I.: Brinda Emu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 07/25/2014 - ongoing

Agency: Massachusetts General Hospital
I.D.#: 1501015241
Title: Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults (REPRIEVE)
P.I.: Jessica Tuan
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/18/2015 - ongoing

Agency: University of Massachusetts
I.D.#: 2000021845REG
Title: Mechanisms of HIV latency
P.I.: Ya-Chi Ho
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 04/19/2018 - ongoing

Agency: Johns Hopkins University
I.D.#: 2000025220
Title: HOPE in Action Trial of HIV+ Deceased Donor Liver Transplants for HIV+ Recipients
P.I.: Maricar Malinis
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/16/2019 - ongoing

Agency: Gilead Sciences
I.D.#: 2000027515
Title: Study to Evaluate the Safety and Efficacy of Lenacapavir in Combination With an Optimized Background Regimen in Heavily Treatment Experienced Participants Living With HIV-1 Infection With Multidrug Resistance (CAPELLA)
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/13/2020 - ongoing

Agency: Gilead Sciences
I.D.#: 2000034216
Title: An Umbrella Phase 1b, Open-label, Multi-Cohort Study to Evaluate Safety, Pharmacokinetics, and Antiviral Activity of Novel Antiretrovirals in Participants With HIV-1 (GS-US-544-5905)
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/16/2023 - ongoing

Past Grants

Agency: HRSA
I.D.#: H4AHA22762

Title:	Expanding HIV Training Track in the Yale Graduate Medical Education Residency Program.
P.I.:	Lydia Aoun Barakat
Role:	PI
Percent effort:	20%
Total costs:	$300,000.00
Project period:	09/01/2011 - 06/30/2015

Agency:	HRSA
I.D.#:	H
Title:	PEER: Workforce Development in Liberia
P.I.:	Onyema Ogbuagu
Role:	Consultant/Mentor
Percent effort:	5%
Total costs:	$500,000.00
Project period:	03/01/2018 - 02/28/2021

Past Clinical Trials

Agency:	Gilead Sciences
I.D.#:	1003006556
Title:	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naïve Adults (GS-US-236-0102 Amendment 12, dated 08 April 201019 January 2012)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	17420.0000/patient
Project period:	05/14/2010 - 05/07/2014

Agency:	Gilead Sciences
I.D.#:	1005006755
Title:	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV 1 Infected, Antiretroviral Treatment-Naïve Adults (GS-US-236-0103)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	17420.0000/patient
Project period:	06/11/2010 - 05/11/2015

Agency:	Gilead Sciences
I.D.#:	1105008478

Title:	A Phase 3 Open-label Safety Study of Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients with Mild to Moderate Renal Impairment (GS-US-236-0118, Amend 1, 26 Oct 2011)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/16/2011 - 05/20/2014

Agency:	Schering Plough Corporation
I.D.#:	1107008828
Title:	An Open-Label, One-Period Study in Patients Receiving Methadone or Buprenorphine/Naloxone Maintenance Therapy to Evaluate the Effect of SCH 503034 (Boceprevir) on Either Methadone or Buprenorphine/Naloxone Plasma Concentrations
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	09/21/2011 - 07/29/2014

Agency:	Gilead Sciences
I.D.#:	1302011480
Title:	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Versus Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults (GS-US-292-0104)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/04/2013 - 03/08/2017

Agency:	Gilead Sciences
I.D.#:	1303011614
Title:	A Study of the Concordance of Knowledge And Beliefs Held by Patients Infected with HIV and Their HIV Health Care Providers Regarding Single Tablet Regimens (STR) (KNABSTR study)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/11/2013 - 03/22/2019

Agency:	Gilead Sciences
I.D.#:	1303011735
Title:	A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Elvitegravir/Cobicistat/Emtricitabine/ Tenofovir Alafenamide Versus

	Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Positive, Antiretroviral Treatment-Naïve Adults (GS-US-292-0111)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/17/2013 - 03/05/2014

Agency:	Gilead Sciences
I.D.#:	1304011909
Title:	A Phase 3, Open Label Study to Evaluate Switching from a TDF-Containing Combination Regimen to a TAF-Containing Combination Single Tablet Regimen (STR) in Virologically Suppressed, HIV 1 Positive Subjects (GS-US-292-0109 Amendment 1 dated 19 February 2013)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/15/2013 - 05/23/2017

Agency:	Gilead Sciences
I.D.#:	1304011940
Title:	A Phase 3 Open-label Safety Study of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen in HIV-1 Positive Patients with Mild to Moderate Renal Impairment (GS-US-292-0112, 5 February 2013)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/15/2013 - 03/17/2014

Agency:	ViiV Healthcare Company
I.D.#:	1403013655
Title:	A Phase IIIb, randomized, open-label study of the safety and efficacy of dolutegravir/abacavir/lamivudine once daily compared to atazanavir and ritonavir plus tenofovir/emtricitabine once daily in HIV-1 infected antiretroviral therapy naïve women (the ARIA study)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/04/2014 - 11/12/2014

Agency:	Merck Sharp Dohme LLC
I.D.#:	1406014182
Title:	A Phase III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172/MK-8742 in Treatment-Naïve Subjects with

	Chronic HCV GT1, GT4, GT5 and GT6 Infection who are on Opiate Substitution Therapy
P.I.:	Frederick Lewis Altice
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	7191.0000/patient
Project period:	07/16/2014 - 02/25/2019

Agency:	Gilead Sciences
I.D.#:	1502015373
Title:	A Phase 3b, Randomized, Double-Blind Switch Study to Evaluate the Safety and Efficacy of Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) Fixed Dose Combination (FDC) in HIV-1 Positive Subjects who are Virologically-Suppressed on Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate (FTC/RPV/TDF)
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/27/2015 - 07/18/2018

Agency:	Bristol-Myers Squibb Company
I.D.#:	1502015357
Title:	A Multi-arm, Phase 3, Randomized, Placebo Controlled, Double Blind Clinical Trial to Investigate the Efficacy and Safety of BMS-663068 in Heavily Treatment Experienced Subjects Infected with Multi-drug Resistant HIV-1
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/08/2015 - 06/29/2018

Agency:	Gilead Sciences
I.D.#:	1502015358
Title:	Phase 3b, Randomized, Double-Blind Study to Evaluate Switching from a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Subjects
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	04/29/2015 - 07/02/2018

Agency:	Bristol-Myers Squibb Company
I.D.#:	1503015534

Title:	A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-1 Infected Adults
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/04/2015 - 03/22/2016

Agency:	ViiV Healthcare Company
I.D.#:	1507016203
Title:	Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	09/01/2015 - 02/15/2018

Agency:	TaiMed Biologics Inc.
I.D.#:	1511016791
Title:	A Phase 3, Single Arm, 24-Week, Multicenter Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant HIV-1
P.I.:	Brinda Emu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	01/05/2016 - 05/17/2017

Agency:	CytoDyn, Inc.
I.D.#:	1603017498
Title:	A Randomized, Double-blind, Placebo-controlled Trial, Followed by Single-arm Treatment of PRO 140 in Combination w/ Optimized Background Therapy in Treatment-Experienced HIV Subjects (PRO 140)
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/12/2016 - 03/19/2019

Agency:	Hologic, Inc.
I.D.#:	1607018158
Title:	Clinical Evaluation of the Aptima® Combo 2® Assay Using the Panther® System in Female Urine Samples
P.I.:	Dana Dunne

Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 08/30/2016 - 06/13/2017

Agency: TaiMed Biologics Inc.
I.D.#: 1608018251
Title: A Phase 3, Multicenter, Expanded Access Study of Ibalizumab Plus an Optimized Background Regimen (OBR) in Treatment-Experienced Patients Infected With Multi-Drug Resistant (MDR) HIV-1
P.I.: Brinda Emu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 09/21/2016 - 12/10/2018

Agency: Gilead Sciences
I.D.#: 1608018342
Title: Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/07/2016 - 05/21/2021

Agency: CytoDyn, Inc.
I.D.#: 2000020372
Title: Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/17/2017 - 07/05/2023

Agency: YCCI Pilot Project Grant
I.D.#: 2000020907
Title: Antiretroviral Toxicity and Mitochondrial Study (ATM-Study)
P.I.: Elijah Paintsil
Role: Sub-Investigator
Percent effort: N/A

Total costs: -
Project period: 05/16/2017 - 05/28/2021

Agency: Roche Diagnostics Operations, Inc.
I.D.#: 2000021900
Title: Performance Evaluation: Elecsys® HIV Duo on the cobas e 801 Immunoassay Analyzer Sample Collection
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/20/2017 - 11/26/2018

Agency: ViiV Healthcare Company
I.D.#: 2000023674
Title: Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 02/28/2018 - 07/21/2021

Agency: Gilead Sciences
I.D.#: 2000024090
Title: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Fixed Dose Combination of Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment Naïve, HIV-1 and Hepatitis B Co-Infected Adults
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 10/29/2018 - 09/17/2020

Agency: CytoDyn, Inc.
I.D.#: 2000025383
Title: A Multi-center, Two-Part, Single-Arm, Open Label, 25-Week Trial With PRO 140 in Treatment-Experienced HIV-1 Subjects
P.I.: Onyema Ogbuagu
Role: Sub-Investigator
Percent effort: N/A
Total costs: -
Project period: 05/28/2019 - 03/03/2023

Agency: ViiV Healthcare Company

I.D.#:	2000026468
Title:	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed (SALSA)
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	12/17/2019 - 11/15/2021

Agency:	Merck Sharp Dohme LLC
I.D.#:	2000027222
Title:	Phase 3, Randomized, Clinical Study in HIV-1-Infected Heavily Treatment-Experienced Participants Evaluating the Antiretroviral Activity of Blinded Islatravir (ISL), Doravirine (DOR), and Doravirine/Islatravir (DOR/ISL), Each Compared to Placebo, and the Antiretroviral Activity, Safety, and Tolerability of Open-Label DOR/ISL
P.I.:	Thilinie D Bandaranayake
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/18/2020 - 10/12/2021

Agency:	Gilead Sciences
I.D.#:	2000027734
Title:	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/21/2020 - 11/06/2020

Agency:	Gilead Sciences
I.D.#:	2000027732
Title:	Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734™) in Participants With Severe Coronavirus Disease (COVID-19)
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/21/2020 - 11/06/2020

Agency:	Gilead Sciences
I.D.#:	2000027522
Title:	A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination With Other Antiretroviral Agents in People Living With HIV
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	07/16/2020 - 09/18/2020

Agency:	ViiV Healthcare Company
I.D.#:	2000029306
Title:	A Study to Evaluate Efficacy and Safety of Cabotegravir (CAB) Long Acting (LA) Plus (+) Rilpivirine (RPV) LA Versus BIKTARVY® (BIK) in Participants With Human Immunodeficiency Virus (HIV)-1 Who Are Virologically Suppressed (SOLAR)
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	03/17/2021 - 01/13/2023

Agency:	Yale University School of Medicine
I.D.#:	2000030266
Title:	Qualitative and Quantitative Assessment of SARS-CoV-2 Immunogenicity after COVID-19 Vaccination in HIV-Positive Individuals
P.I.:	Jessica Tuan
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	200.0000
Project period:	03/23/2021 - 03/09/2022

Agency:	Gilead Sciences
I.D.#:	2000030509
Title:	Study to Evaluate the Safety and Efficacy of GS-5423 and GS-2872 in Combination With Lenacapavir (GS-6207) in Virologically Suppressed Adults With HIV-1 Infection
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/12/2021 - 06/27/2022

Pending Clinical Trials

Agency:	Center for Interdisciplinary Research on AIDS (CIRA)
I.D.#:	2000028033
Title:	Understanding the impact of COVID-19 on individuals with HIV: a mixed methods study
P.I.:	E. Jennifer Edelman
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/07/2020 - ongoing

Agency:	Yale University School of Medicine
I.D.#:	2000033193
Title:	The Effects of Antiretroviral Therapy on immune activation, inflammation, cellular changes and clinical outcomes in Elite Controllers
P.I.:	Lydia Aoun-Barakat
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	10/12/2022 - ongoing

Agency:	Gilead Sciences
I.D.#:	2000033452
Title:	An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens GS-US-621-6289
P.I.:	Onyema Ogbuagu
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	01/05/2023 - ongoing

Agency:	Health Resources and Services Administration
I.D.#:	2000035072
Title:	Emerging Strategies to Improve Health Outcomes for People Aging with HIV: PROJECT I-CARE-4-PAH: Intervention for Collaborative Care to Assess Risk and Eliminate polyPharmacy, Falls, and Fragility Fractures, for People Aging with HIV
P.I.:	Lydia Aoun-Barakat
Role:	Principal Investigator
Percent effort:	N/A
Total costs:	-
Project period:	05/30/2023 - ongoing

Agency:	Yale University School of Medicine
I.D.#:	2000035414
Title:	Social determinants of health and cancer screening in people living with HIV
P.I.:	Mark Lustberg
Role:	Sub-Investigator
Percent effort:	N/A
Total costs:	-
Project period:	06/05/2023 - ongoing

Invited Speaking Engagements, Presentations & Workshops Not Affiliated With Yale:

International/National

1. "Quality Improvement in HIV Care". HRSA, Ryan White All Grantees Meeting, Washington, DC, August 2008. (Demonstration)
2. "Expanding HIV Training in Graduate Medical Education". HRSA, National Ryan White Conference, Washington, DC, August 2012. (Lecture)
3. "Ending AIDS- Prospects of Treatment Toward HIV Cure". Annual Lebanese Infectious Disease Congress, Beirut, Beirut Governorate, Lebanon, March 2017. (Lecture)
4. "HIV Epidemic- Successes and Challenges". Redemption Hospital, Medical Grand Round, Monrovia, Montserrado, Liberia, April 2019. (Lecture)
5. "HIV Management". John F. Kennedy Hospital, Workshop, Monrovia, Montserrado, Liberia, April 2019. (Lecture)
6. "HIV Quality Management". John F. Kennedy Hospital , Workshop, Zoom meeting, November 2020. (Lecture)
7. "Intersection between HIV and COVID-19". Medical Grand Round, Zoom meeting, January 2021. (Lecture)
8. "HIV Pathway Initiative – Presentation". HRSA-HIV/AIDS Bureau, Zoom meeting, February 2021. (Demonstration)
9. "Update on HIV treatment-40 years later". Annual Lebanese Infectious Disease Congress, Zoom Meeting, March 2021. (Lecture)
10. "Infectious Disease Diversity, Equity, and Antiracism (ID2EA): A Dedicated Curriculum for Infectious Disease Professionals". IDSA, ID Week 2021, Virtual Meeting, October 2021. (Oral Presentation)
11. "The HIV Epidemic- Lessons Learned". Lebanese-American University, Medical Grand Round, Beirut, Beirut Governorate, Lebanon, May 2022. (Lecture)
12. "HIV Workforce Development". American University of Beirut, Workshop, Beirut, Beirut Governorate, Lebanon, May 2022. (Lecture)
13. "HIVMA HIV workforce development". HRSA HIV/AIDS Bureau leadership, Zoom Presentation, September 2022. (Demonstration)
14. "Ending the HIV Epidemic: The Key Pillar of Workforce Development". University of Virginia, HIV Symposium, Charlottesville, VA, February 2023. (Lecture)
15. "Management of HIV Resistance- Available Treatment Modalities". Lebanese-American University, Anti-microbial resistance symposium, Beirut, Beirut Governorate, Lebanon, March 2023. (Lecture)
16. "HIV and Aging: People-Purpose-Power". P3 summit 2023 , Austin, TX, July 2023. (Lecture)

17. "Moderator: State of the ART for HIV Care and Prevention". IDSA/HIVMA, ID week 2023, Boston, MA, October 2023. (Oral Presentation)

Regional

1. "HIV Update". CT DPH HIV Seminar, Hartford, CT, January 2012. (Lecture)
2. "Retention in Care of HIV-infected Youth". UMASS, Primary Care Symposium, New Haven, CT, June 2013. (Lecture)
3. "Top 10 articles in Infectious Diseases". CIDS Annual Meeting, Orange, CT, May 2014. (Lecture)
4. "Challenging Cases in Infectious Diseases". CIDS Annual Meeting, Orange, CT, May 2015. (Lecture)
5. "Is PrEP for Women". Southern University Panel discussion- PrEP Town Hall meeting for HIV prevention, New Haven, CT, January 2016. (Lecture)
6. "Caring for HIV/AIDS patients and potential career paths in the field of infectious disease". Quinnipiac University-Panel discussion, New Haven, CT, March 2016. (Lecture)
7. "Ending AIDS is every clinician's opportunity" CT state course mandate". NEAETC, CT Course Mandate, New Haven, CT, April 2016. (Lecture)
8. "Expanding HIV Training in GME-The Yale experience". SUNY Symposium, New York, NY, January 2017. (Lecture)
9. "HIV Case Discussion". UCONN ID Fellow Symposium, Farmington, CT, March 2018. (Lecture)
10. "The Changing Face of HIV Epidemic". UCONN, Medical Grand Round, Farmington, CT, March 2018. (Lecture)
11. "Time to End AIDS". New Haven Mayor's Task Force on AIDS, AIDS Walk New Haven Keynote Speaker, New Haven, CT, April 2018. (Address)
12. "HIV Treatment Update: Caring for the Full Spectrum of Patients Living with HIV, from the Everyday to the Esoteric". AAHIVM Symposium, New Haven, CT, January 2019. (Lecture)
13. "Ending the HIV Epidemic". New Haven Mayor's Task Force on AIDS, AIDS Walk New Haven Keynote Speaker, New Haven, CT, April 2020. (Address)

Peer-Reviewed Presentations Given at Meetings Not Affiliated With Yale:

International/National

1. Infectious Disease Diversity, Equity, and Antiracism (ID2EA): A Dedicated Curriculum for Infectious Disease Professionals. IDSA, ID Week 2021, Virtual meeting, October 2021. (Oral Presentation)

Regional

1. CIDS. 34th Annual Conference for the Connecticut Infectious Disease Society, 2016. Conferencee Co-director, Orange, CT, May 2016. (Lecture)
2. SGIM Annual Meeting. The Changing Face of HIV Care: Expanding HIV Training in Internal Medicine Residency. SGIM , New Haven, CT, May 2016. (Oral Presentation)
3. CIDS. 35th Annual Conference for the Connecticut Infectious Disease Society. Conference Co-director, Orange, CT, May 2017. (Other)
4. CIDS. 36th Annual Conference for the Connecticut Infectious Disease Society. Conference Co-director, New Haven, CT, May 2018. (Other)

5. CIDS. 37th Annual Conference for the Connecticut Infectious Disease Society. Conference Co-director, New Haven, CT, May 2019. (Other)
6. NEAETC. COVID-19 Symposium. Co-director, Zoom, January 2020. (Other)
7. NEAETC. Primary Care for HIV. Primary Care Symposium Co-director, Zoom, June 2020. (Other)
8. NEAETC. Connecticut Triple Threat. EHE Symposium Co-director, Zoom , February 2021. (Other)
9. NEAETC. Health Equity Summit: Health for All- Symposium Co-director. NEAETC, Zoom , June 2021. (Other)
10. NEAETC. Ending the HIV Epidemic: Through a Syndemic Lens. CT DPH Summit Co-director, Zoom , June 2022. (Other)

Professional Service:

Peer Review Groups/Grant Study Sections

2020 - Present Reviewing Editor, NIH/DHHS Opportunistic Infections Guidelines reviewer

Professional Organizations

AAHIVM

2018 - Present Steering Committee member, AAHIVM

American Academy of HIV Medicine

2017 - Present Board of Directors, American Academy of HIV Medicine, New England Executive Board Member

CT Department of Public Health Reportable Disease Advisory

2016 - Present Medical Advisor, CT Department of Public Health Reportable Disease Advisory

CT Infectious Disease Society

2015 - 2022 Executive Board Member, CT Infectious Disease Society
2017 - 2019 President, CT Infectious Disease Society, President

CT Infectious Disease Society

2014 - 2017 Newsletter Editor, CT Infectious Disease Society

IDSA

2000 - Present Member, IDSA
2021 - Present Abstract Reviewer, IDSA
2023 - Present Fellow, IDSA

IDSA Education Committee

2018 - 2021 Board Member, IDSA Education Committee

IDSA/HIVMA

2021 - Present Board of Directors, IDSA/HIVMA
2021 - Present Award Committee Member, IDSA/HIVMA

IDSA/HIVMA Award Committee

2023 - Present Vice Chair, IDSA/HIVMA Award Committee, IDSA/HIVMA Award Committee

IDSA/HIVMA Workforce Development

2022 - Present Committee Member, IDSA/HIVMA Workforce Development, Workforce Development

National HIV Residency Pathway Consortium

2020 - Present Steering Committee member, National HIV Residency Pathway Consortium

New Haven County Medical Association

2020 - Present Executive Board Member, New Haven County Medical Association
2023 - Present Vice President, New Haven County Medical Association

Yale University / Hospital System

Medical School

2018 - Present Board Member, SWIM
2023 - Present Faculty Member, Pediatric ID Section Chief Search Committee

Department

2010 - Present Investigator, Yale AIDS Program Clinical Trials committee
2012 - Present Member, Clinical Competency Committee for the ID Fellowship Program
2013 - Present Member, Clinical Competency Committee for the Yale Primary Care Residency Program
2013 - Present Member, Department of Medicine Clinical Chiefs and Medical Directors Committee
2018 - 2020 Medical Advisor, Yale Medicine Clinical Optimization Committee
2020 - 2022 Co-Founder, ID Section Diversity Equity and Antiracism Curriculum (ID2EA)
2020 - Present Member, ID Section Diversity Equity and Antiracism Curriculum (ID2EA)
2020 - Present Member, Department of Medicine DEI Committee
2020 - Present Co-Chair, Department of Medicine DEI - Retention Committee
2021 - Present Member, Department of Medicine Quality and Safety Committee

Public Service / Media Presence

Public Service

2012 - 2013	Volunteer, NAACP Volunteer New Haven Health Fair
2014 - 2019	Volunteer, YNHH Refugee Clinic
2017 - Present	Committee Member, New Haven Mayor's Task Force on AIDS
2020 - Present	Executive Board Member, New Haven County Medical Association
2021 - 2022	Volunteer, YNHH Volunteer vaccinator for COVID-19

Bibliography:

Peer-Reviewed Original Research

1. Barakat LA, Quentzel HL, Jernigan JA, Kirschke DL, Griffith K, Spear SM, Kelley K, Barden D, Mayo D, Stephens DS, Popovic T, Marston C, Zaki SR, Guarner J, Shieh WJ, Carver HW, Meyer RF, Swerdlow DL, Mast EE, Hadler JL, Team F. Fatal Inhalational Anthrax in a 94-Year-Old Connecticut Woman. JAMA 2002, 287: 863-868. PMID: 11851578, DOI: 10.1001/jama.287.7.863.
2. Hasbun R, Vikram HR, Barakat LA, Buenconsejo J, Quagliarello VJ. Complicated Left-Sided Native Valve Endocarditis in Adults: Risk Classification for Mortality. JAMA 2003, 289: 1933-1940. PMID: 12697795, DOI: 10.1001/jama.289.15.1933.
3. Peluso MJ, Chia D, Sheen W, Hutchinson C, **Barakat L**. Infectious mimicry complicates diagnosis in hemophagocytic syndrome caused by anaplastic large-cell lymphoma. Case Reports In Medicine 2012, 2012: 968706. PMID: 22761627, PMCID: PMC3385285, DOI: 10.1155/2012/968706.
4. Selvaraj S, Ghebremichael M, Li M, Foli Y, Langs-Barlow A, Ogbuagu A, Barakat L, Tubridy E, Edifor R, Lam W, Cheng Y, Paintsil E. Antiretroviral Therapy–Induced Mitochondrial Toxicity: Potential Mechanisms Beyond Polymerase-γ Inhibition. Clinical Pharmacology Therapeutics 2014, 96: 110-120. PMID: 24637942, PMCID: PMC4065195, DOI: 10.1038/clpt.2014.64.
5. Walker WE, Kurscheid S, Joshi S, Lopez CA, Goh G, Choi M, Barakat L, Francis J, Fisher A, Kozal M, Zapata H, Shaw A, Lifton R, Sutton RE, Fikrig E. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers. Journal Of Virology 2015, 89: 5502-5514. PMID: 25740989, PMCID: PMC4442529, DOI: 10.1128/jvi.00118-15.
6. Barakat LA, Juthani-Mehta M, Allore H, Trentalange M, Tate J, Rimland D, Pisani M, Akgün KM, Goetz MB, Butt AA, Rodriguez-Barradas M, Duggal M, Crothers K, Justice AC, Quagliarello VJ. Clinical outcomes of HIV-infected men with CAP. HIV Medicine 2015, 16: 421-430. PMID: 25959543, PMCID: PMC5015437, DOI: 10.1111/hiv.12244.
7. Cowell A, Shenoi SV, Kyriakides TC, Friedland G, Barakat LA. Trends in hospital deaths among human immunodeficiency virus–infected patients during the antiretroviral therapy era, 1995 to 2011. Journal Of Hospital Medicine 2015, 10: 608-614. PMID: 26130520, PMCID: PMC4560992, DOI: 10.1002/jhm.2409.
8. JGIM, 2016; 31: S295-296
9. Helou E, Shenoi S, Kyriakides T, Landry ML, Kozal M, Barakat LA. Characterizing Patients with Very-Low-Level HIV Viremia: A Community-Based Study. Journal Of The International Association Of Providers Of AIDS Care (JIAPAC) 2016, 16: 261-266. PMID: 27903948, PMCID: PMC5423832, DOI: 10.1177/2325957416680028.
10. Wang'ondu R., Samuels S., Paintsil E., Barakat LA, Andiman W. Langs A. 2018 doi/full/10.1080/23311886.2018.1463816

11. Yamhiro A, Frank C, Wang Q, Li F, Barakat LA, Kozal M. HIV AIDS August 2018. doi.org/10.16966/2380-5536.158
12. Ogbuagu O, Marshall BDL, Tiberio P, Ogunbajo A, Barakat L, Montgomery M, Almonte A, Wray T, Williams EC, Edelman EJ, Chan PA. Prevalence and Correlates of Unhealthy Alcohol and Drug Use Among Men Who Have Sex with Men Prescribed HIV Pre-exposure Prophylaxis in Real-World Clinical Settings. AIDS And Behavior 2018, 23: 190-200. PMID: 30145707, PMCID: PMC7020905, DOI: 10.1007/s10461-018-2260-9.
13. Zapata HJ, Van Ness PH, Avey S, Siconolfi B, Allore HG, Tsang S, Wilson J, Barakat L, Mohanty S, Shaw AC. Impact of Aging and HIV Infection on the Function of the C-Type Lectin Receptor MINCLE in Monocytes. The Journals Of Gerontology Series A 2018, 74: 794-801. PMID: 30239628, PMCID: PMC6521921, DOI: 10.1093/gerona/gly209.
14. Barakat LA, Dunne DW, Tetrault JM, Soares S, Chia D, Ogbuagu OE, Moriarty JP, Huot SJ, Green ML. The Changing Face of HIV Care. Academic Medicine 2018, 93: 1673-1678. PMID: 29901657, DOI: 10.1097/acm.0000000000002317.
15. Sherbuk JE, **Barakat LA**. Training the next generation of HIV providers: impact of trainees on patient satisfaction in an urban HIV clinic. AIDS Care 2019, 31: 41-44. PMID: 29779395, DOI: 10.1080/09540121.2018.1476663.
16. Rizk C, Miceli J, Shiferaw B, Malinis M, Barakat L, Ogbuagu O, Villanueva M. Implementing a Comprehensive HCV Clinic within an HIV Clinic: A Model of Care for HCV Micro-elimination. Open Forum Infectious Diseases 2019, 6: ofz361. PMID: 31412130, PMCID: PMC6785669, DOI: 10.1093/ofid/ofz361.
17. Dunne D, Green M, Tetrault J, Barakat LA. Development of a Novel Competency-Based Evaluation System for HIV Primary Care Training: the HIV Entrustable Professional Activities. Journal Of General Internal Medicine 2019, 35: 331-335. PMID: 31667752, PMCID: PMC6957645, DOI: 10.1007/s11606-019-04956-1.
18. Sopeyin A, Zhou L, Li M, Barakat L, Paintsil E. Dysregulation of sterol regulatory element-binding protein 2 gene in HIV treatment-experienced individuals. PLOS ONE 2019, 14: e0226573. PMID: 31846498, PMCID: PMC6917281, DOI: 10.1371/journal.pone.0226573.
19. Edelman EJ, **Aoun-Barakat L**, Villanueva M, Friedland G. Confronting Another Pandemic: Lessons from HIV can Inform Our COVID-19 Response. AIDS And Behavior 2020, 24: 1977-1979. PMID: 32399798, PMCID: PMC7215127, DOI: 10.1007/s10461-020-02908-z.
20. Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M, Paczkowski P, Cruz CD, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, **Aoun Barakat L**. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. Research Square 2020 PMID: 32702723, PMCID: PMC7336693, DOI: 10.21203/rs.3.rs-28583/v1.
21. Price CC, Altice FL, Shyr Y, Koff A, Pischel L, Goshua G, Azar MM, Mcmanus D, Chen SC, Gleeson SE, Britto CJ, Azmy V, Kaman K, Gaston DC, Davis M, Burrello T, Harris Z, Villanueva MS, **Aoun-Barakat L**, Kang I, Seropian S, Chupp G, Bucala R, Kaminski N, Lee AI, LoRusso PM, Topal JE, Dela Cruz C, Malinis M. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019 Survival and Clinical Outcomes. CHEST Journal 2020, 158: 1397-1408. PMID: 32553536, PMCID: PMC7831876, DOI: 10.1016/j.chest.2020.06.006.
22. Farhadian S, Glick LR, Vogels CBF, Thomas J, Chiarella J, Casanovas-Massana A, Zhou J, Odio C, Vijayakumar P, Geng B, Fournier J, Bermejo S, Fauver JR, Alpert T, Wyllie AL, Turcotte C, Steinle M,

Paczkowski P, Dela Cruz C, Wilen C, Ko AI, MacKay S, Grubaugh ND, Spudich S, Barakat LA. Acute encephalopathy with elevated CSF inflammatory markers as the initial presentation of COVID-19. BMC Neurology 2020, 20: 248. PMID: 32552792, PMCID: PMC7301053, DOI: 10.1186/s12883-020-01812-2.

23. Yasin F, Rizk C, Taylor B, Barakat LA. Substantial gap in primary care: older adults with HIV presenting late to care. BMC Geriatrics 2020, 20: 438. PMID: 33129258, PMCID: PMC7603686, DOI: 10.1186/s12877-020-01842-y.
24. Hysell K, Yusuf R, Barakat L, Virata M, Gan G, Deng Y, Perez-Irizarry J, Vega T, Goldberg SB, Emu B. Decreased Overall Survival in HIV-associated Non–small-cell Lung Cancer. Clinical Lung Cancer 2020, 22: e498-e505. PMID: 33468393, PMCID: PMC8169710, DOI: 10.1016/j.cllc.2020.11.006.
25. Virata M, Villanueva M, Shenoi S, Ladines-Lim J, **Aoun-Barakat L**. 543. SARS-CoV-2 Viral Dynamics For Symptomatic People Living with HIV Requiring Hospitalization For COVID-19. Open Forum Infectious Diseases 2020, 7: s338-s338. PMCID: PMC7777445, DOI: 10.1093/ofid/ofaa439.737.
26. Ferzacca E, Dunne D, Barbieri A, **Aoun-Barakat L**. 1546. Update in Syphilis Proctitis: Insights from a Case Series and Literature Review. Open Forum Infectious Diseases 2020, 7: s772-s773. PMCID: PMC7777609, DOI: 10.1093/ofid/ofaa439.1726.
27. Ferzacca E, Barbieri A, Barakat L, Olave MC, Dunne D. Lower Gastrointestinal Syphilis: Case Series and Literature Review. Open Forum Infectious Diseases 2021, 8: ofab157-. PMID: 34631920, PMCID: PMC8494075, DOI: 10.1093/ofid/ofab157.
28. Pischel L, Walelo M, Benson J, Osborn R, Schrier R, Tuan J, Barakat L, Ogbuagu O. Race and ethnicity do not impact eligibility for remdesivir: A single-center experience. PLOS ONE 2021, 16: e0250735. PMID: 33956849, PMCID: PMC8101938, DOI: 10.1371/journal.pone.0250735.
29. Tuan JJ, Zapata H, Critch-Gilfillan T, Ryall L, Turcotte B, Mutic S, Andrews L, Roh ME, Friedland G, Barakat L, Ogbuagu O. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV. HIV Medicine 2021, 23: 178-185. PMID: 34632695, PMCID: PMC8652674, DOI: 10.1111/hiv.13188.
30. Ogbuagu O, Wachekwa I, Yasin F, Nuta C, Donato S, Toomey J, Adeiza M, Barakat LA. High HIV Detection in a Tertiary Facility in Liberia: Implications and Opportunities. Annals Of Global Health 2021, 87: 117. PMID: 34900617, PMCID: PMC8622250, DOI: 10.5334/aogh.3243.
31. Virata MD, Shenoi SV, Ladines-Lim J, Villanueva MS, Barakat LA. Cumulative burden of non-communicable diseases predicts COVID hospitalization among people with HIV: A one-year retrospective cohort study. PLOS ONE 2021, 16: e0260251. PMID: 34851963, PMCID: PMC8635326, DOI: 10.1371/journal.pone.0260251.
32. Shenoi S, Sideleau R, McKay S, **Aoun-Barakat L**. 856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics. Open Forum Infectious Diseases 2021, 8: s519-s519. DOI: 10.1093/ofid/ofab466.1051.
33. 33. Zhao A, Rizk Ch, Zhao X, Esu A, Deng Y, Barakat LA, Villanueva M. Open Forum Infectious Diseases, 2022. https://doi.org/10.1093/ofid/ofac196
34. Harsono D, Deng Y, Chung S, Barakat LA, Friedland G, Meyer JP, Porter E, Villanueva M, Wolf MS, Yager JE, Edelman EJ. Experiences with Telemedicine for HIV Care During the COVID-19 Pandemic: A Mixed-Methods Study. AIDS And Behavior 2022, 26: 2099-2111. PMID: 35064390, PMCID: PMC8782707, DOI: 10.1007/s10461-021-03556-7.
35. Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, **Aoun-Barakat L**, Virata M, Olivares M, Wickersham JA. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the

United States: Findings from a National Survey. Vaccines 2022, 10: 424. PMID: 35335054, PMCID: PMC8949562, DOI: 10.3390/vaccines10030424.

36. Zhao A, Rizk C, Zhao X, Esu A, Deng Y, Barakat L, Villanueva M. Longitudinal Improvements in Viral Suppression for Persons With New HIV Diagnosis Receiving Care in the Ryan White Program: A 10-Year Experience in New Haven, CT (2009–2018). Open Forum Infectious Diseases 2022, 9: ofac196. PMID: 35794946, PMCID: PMC9251657, DOI: 10.1093/ofid/ofac196.
37. Wickersham JA, Meyer JP, Shenoi S, Altice FL, Barakat LA, Virata M, Olivares M, Maviglia F, Khati A, Shrestha R. Willingness to Be Vaccinated Against COVID-19 Among People With HIV in the United States: Results From a National Survey. Frontiers In Medicine 2022, 9: 886936. PMID: 35847816, PMCID: PMC9280331, DOI: 10.3389/fmed.2022.886936.
38. Li G, Park LS, Lodi S, Logan RW, Cartwright EJ, **Aoun-Barakat L**, Casas JP, Dickerman BA, Rentsch CT, Justice AC, Hernán MA. Tenofovir disoproxil fumarate and coronavirus disease 2019 outcomes in men with HIV. AIDS 2022, 36: 1689-1696. PMID: 35848570, PMCID: PMC9444875, DOI: 10.1097/qad.0000000000003314.
39. Tuan JJ, Zapata H, Barakat L, Andrews L, Behnegar A, Kim YW, Kayani J, Mutic S, Ryall L, Turcotte B, Critch-Gilfillan T, Zhao M, Salahuddin S, Gupta S, Sutton R, Friedland G, Emu B, Ogbuagu O. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH). BMC Infectious Diseases 2022, 22: 744. PMID: 36131232, PMCID: PMC9491266, DOI: 10.1186/s12879-022-07737-0.
40. Carson H, Wang K, Paek H, Hoffman P, Arakaki A, Gonzalez-Colaso R, Barakat L, Villanueva M, Womack J. Equity and use of telehealth modalities among people living with HIV during the COVID-19 pandemic. Digital Health 2023, 9: 20552076231218840. PMID: 38107977, PMCID: PMC10722925, DOI: 10.1177/20552076231218840.
41. Ogbuagu O, Sharma M, Igiraneza G, Andrews L, Tuan J, Barakat L. HIV risk profile and prevention needs of individuals seeking monkeypox (mpox) vaccination in an urban clinic in the U.S.: a brief report. BMC Infectious Diseases 2023, 23: 146. PMID: 36890468, PMCID: PMC9993362, DOI: 10.1186/s12879-023-08075-5.
42. Gleeson S, Zapata H, Bathgate M, Emu B, Frederick J, Friedland G, Golden M, Meyer J, Radin J, Sideleau R, Shaw A, Shenoi S, Trubin P, Virata M, Barakat L, Desruisseaux M. Building an Infectious Disease Diversity, Equity, and Antiracism (ID2EA) Curriculum: A Single Center's Experience and Reflections. Clinical Infectious Diseases 2023, 77: 703-710. PMID: 37078888, DOI: 10.1093/cid/ciad236.
43. Hao R, Brooks R, Zelenev A, Spinner G, Barakat L, Villanueva M. Expanded or Risk Factor-Based Annual Screening for Hepatitis C Virus (HCV) Among Persons With HIV: Which Is the Best Approach? Health Promotion Practice 2023, 24: 1009-1017. PMID: 37439817, DOI: 10.1177/15248399231169794.
44. Kumar A, Wang J, Esterly A, Radcliffe C, Zhou H, Wyk B, Allore H, Tsang S, Barakat L, Mohanty S, Zhao H, Shaw A, Zapata H. Dectin-1 stimulation promotes a distinct inflammatory signature in the setting of HIV-infection and aging. Aging 2023, 15: 7866-7908. PMID: 37606991, PMCID: PMC10497004, DOI: 10.18632/aging.204927.
45. Harsono D, Deng Y, Chung S, Barakat L, Friedland G, Villanueva M, Yager J, Justen M, Edelman E. Prevalence and Correlates of Physical Inactivity Among Individuals with HIV During the First COVID-19 Wave: A Cross-sectional Survey. AIDS And Behavior 2023, 1-15. PMID: 37824037, DOI: 10.1007/s10461-023-04170-5.

Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus Statements

1. Quentzel H, Barakat LA, Jernigan J, et al. MMWR 2001; 50: 1049-1051
2. Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.

Peer-Reviewed Case Reports and Technical Notes

1. Chabria S, Barakat L, Ogbuagu O. Steroid-exacerbated HIV-associated cutaneous Kaposi's sarcoma immune reconstitution inflammatory syndrome: 'Where a good intention turns bad'. International Journal Of STD AIDS 2016, 27: 1026-1029. PMID: 26769754, DOI: 10.1177/0956462415627735.
2. Sherbuk J, Saly D, Barakat L, Ogbuagu O. Unusual presentation of disseminated Nocardia abscessus infection in a patient with AIDS. BMJ Case Reports 2016, 2016: bcr2016215649. PMID: 27440848, PMCID: PMC4964189, DOI: 10.1136/bcr-2016-215649.
3. Glick LR, Fogel AL, Ramachandran S, Barakat LA. Unilateral laterothoracic exanthem in association with coronavirus disease 2019. JAAD Case Reports 2020, 6: 900-901. PMID: 32835047, PMCID: PMC7372280, DOI: 10.1016/j.jdcr.2020.07.020.
4. Weiss JJ, Spudich S, Barakat L. VZV myelitis with secondary HIV CSF escape. BMJ Case Reports 2021, 14: e241738. PMID: 34187795, PMCID: PMC8245447, DOI: 10.1136/bcr-2021-241738.

Chapters

1. Barakat LA. and Malinis M. Chapter 3: Head, Neck and Orofacial Infections - A Multidisciplinary Approach. 2016
2. Mokhbat J and Barakat LA. Book Chapter: Perioperative Assessment of the Maxillofacial Surgery Patient. Springer 2018

Commentaries, Editorials and Letters

1. Oldfield B, Barakat LA, Edelman J. HIV Specialist December 2018